Danaher Corporation $DHR Holdings Lowered by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 54.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,659 shares of the conglomerate’s stock after selling 7,845 shares during the quarter. CHICAGO TRUST Co NA’s holdings in Danaher were worth $1,320,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WFA of San Diego LLC bought a new stake in shares of Danaher in the 2nd quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in Danaher during the second quarter worth about $27,000. Red Tortoise LLC raised its position in Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares in the last quarter. Heartwood Wealth Advisors LLC acquired a new stake in Danaher in the 3rd quarter valued at about $37,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Danaher during the 2nd quarter valued at about $40,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.2%

NYSE:DHR opened at $224.78 on Friday. The stock has a market cap of $158.77 billion, a PE ratio of 46.35, a price-to-earnings-growth ratio of 4.36 and a beta of 0.89. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock’s 50-day moving average is $220.37 and its two-hundred day moving average is $207.01.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $1.71 earnings per share. As a group, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 target price (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Redburn Partners set a $220.00 price target on Danaher in a report on Wednesday, October 8th. The Goldman Sachs Group started coverage on Danaher in a research note on Tuesday, December 9th. They set a “buy” rating and a $265.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, HSBC upped their target price on Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a report on Monday, December 1st. Twenty-one equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $248.25.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. This represents a 13.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Jefferies reiterated a Buy on Danaher, supporting demand for the shares by reaffirming conviction in the company’s growth profile and portfolio execution. Jefferies Remains a Buy on Danaher (DHR)
• Positive Sentiment: An analyst write-up highlighted expectations that Danaher’s stock will rise, adding to bullish momentum and investor interest in the name. Danaher (NYSE:DHR) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says
• Positive Sentiment: Zacks Research issued small upward revisions to its Q4 2026, Q1 2027 and FY2027 EPS outlook (e.g., Q4 to ~$2.45, Q1 to ~$2.07, FY2027 to ~$9.18). Those modest raises signal slightly stronger forward earnings traction and help offset other mixed datapoints.
• Neutral Sentiment: Zacks also trimmed several near-term 2026 quarter and FY2026 EPS estimates by only a penny or two (Q2/Q3/FY2026 reductions), indicating very slight near-term pressure but nothing that meaningfully changes multi-year earnings power.
• Negative Sentiment: A market note highlighted that shareholders who bought DHR three years ago have seen roughly a 0.9% loss, underscoring the stock’s modest multi‑year underperformance versus some peers and raising questions about valuation relative to growth expectations. Danaher (NYSE:DHR) shareholders have endured a 0.9% loss from investing in the stock three years ago

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.